Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Piyanuch Kongtim, Mary-Elizabeth M. Percival, Timothy J Martins, Guangrong Qin, Niall Curley, Kelda M. Gardner, Sylvia Chien, Jin Dai, Vivian G. Oehler, C. Anthony Blau, Paul C. Hendrie, Ryan D. Cassaday, Anna B. Halpern, Bart L. Scott, Roland B. Walter, Heather Smith, Guido Marcucci, Pamela S. Becker

Blood (2022) 140 (Supplement 1): 1200–1202.

https://doi.org/10.1182/blood-2022-165801

Published: 2022

Journal Articles

Infectious Complications after Intensive Chemotherapy with CLAG-M or '7+3' for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Carla S. Walti, Anna B. Halpern, Hu Xie, E. Lisa Chung, Kelda M. Gardner, Emily M. Huebner, Colleen Delaney, Catherine Liu, Steven A. Pergam, Guang-Shing Cheng, Louise E. Kimball, Wendy M. Leisenring, Michael Boeckh, Roland B. Walter, Joshua A. Hill

Blood (2021) 138 (Supplement 1): 2339.

https://doi.org/10.1182/blood-2021-144908

Published: 2021

Journal Articles

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Colin D. Godwin, Yi Zhou, Megan Othus, Mallette M. Asmuth, Carole M. Shaw, Kelda M. Gardner, Brent L. Wood, Roland B. Walter, Elihu H. Estey

Blood (2021) 137 (4): 569–572.

https://doi.org/10.1182/blood.2020006219

Published: 2021

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Colin D. Godwin, MDMPhil, Yi Zhou, MD PhD, Megan Othus, PhD, Carole M. Shaw, BA, Kelda M. Gardner, PA-C, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2729.

https://doi.org/10.1182/blood-2019-127128

Published: 2019

Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Blood (2018) 132 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2018-99-116908

Published: 2018

Journal Articles

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Frances Linzee Mabrey, MD, Kelda M Gardner, PA-C, Kathleen Shannon Dorcy, RN, PhD, Andrea Perdue, PA-C, Heather Smith, PA-C, Alicyn Marie Davis, ARNP, Cody Hammer, Donelle Rizzuto, RN, Sunny So, RN, Anna Rosen, Kim Quach, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Mary Beth M. Percival, MD, Roland B. Walter, MD PhD MS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 3851.

https://doi.org/10.1182/blood.V130.Suppl_1.3851.3851

Published: 2017

Journal Articles

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

Blood (2017) 130 (Supplement 1): 4622.

https://doi.org/10.1182/blood.V130.Suppl_1.4622.4622

Published: 2017

Journal Articles

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Anna B Halpern, MD, Emily M Huebner, Megan Othus, PhD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Kelda M Gardner, PA-C, Sarah A Buckley, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2017) 130 (Supplement 1): 149.

https://doi.org/10.1182/blood.V130.Suppl_1.149.149

Published: 2017

Journal Articles

Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study

Roland B. Walter, MD, PhD, Bruno C. Medeiros, MD, Kelda M. Gardner, PA-C, Kaysey F. Orlowski, Leonel Gallegos, MD, Bart L Scott, MD, Paul C. Hendrie, MD, PhD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3936.

https://doi.org/10.1182/blood.V122.21.3936.3936

Published: 2013

Journal Articles

Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML

Jennifer E. Vaughn, MD, MSPH, Morgan A. Powell, BS, Kelda M. Gardner, PA-C, Megan Othus, PhD, Rajeev Rajendra, MD, PhD, Donnelle Rizutto, RN, Pamela S. Becker, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Siobán B. Keel, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Janis L. Abkowitz, MD, Elihu H. Estey, MD, Roland B. Walter, MD, PhD

Blood (2013) 122 (21): 2932.

https://doi.org/10.1182/blood.V122.21.2932.2932

Published: 2013

Journal Articles

Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study

Tara L Chen, PharmD, BCOP, Elihu H. Estey, M.D., Megan Othus, PhD, Kelda M. Gardner, PA-C, Lauren Markle, Roland B. Walter, MD, PhD

Blood (2012) 120 (21): 4343.

https://doi.org/10.1182/blood.V120.21.4343.4343

Published: 2012

Journal Articles

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Pamela S. Becker, MD, PhD, Bruno C. Medeiros, MD, Anthony Selwyn Stein, M.D., Frederick R. Appelbaum, MD, Bart L Scott, MD, MS, Colleen Delaney, MD, MSc, Megan Othus, PhD, Paul C. Hendrie, MD, PhD, Kelda M. Gardner, PA-C, Stephen Petersdorf, MD, John M. Pagel, MD, PhD, Roland B. Walter, MD, PhD, Cynthia Parks, Elihu H. Estey, MD

Blood (2012) 120 (21): 3594.

https://doi.org/10.1182/blood.V120.21.3594.3594

Published: 2012

Journal Articles

Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study

Roland B. Walter, MD, PhD, Bruno C. Medeiros, MD, Kelda M. Gardner, PA-C, Elihu H. Estey, MD

Blood (2011) 118 (21): 1541.

https://doi.org/10.1182/blood.V118.21.1541.1541

Published: 2011

Journal Articles

Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study

Roland B. Walter, MD, PhD, Stephanie J. Lee, MD, MPH, Kelda M. Gardner, PA-C, Andrei R. Shustov, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 2161.

https://doi.org/10.1182/blood.V116.21.2161.2161

Published: 2010

Journal Articles

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Victor A. Chow, Kathleen Shannon Dorcy, RN, MN, Ph.C, Stephen H. Petersdorf, MD, Kelda M. Gardner, PA-C, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 3806.

https://doi.org/10.1182/blood.V116.21.3806.3806

Published: 2010

NARROW

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Infectious Complications after Intensive Chemotherapy with CLAG-M or '7+3' for Adults with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Outpatient Intensive Induction Chemotherapy for Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome

Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned

G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial

Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study

Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML

Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study

Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only